Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs Amphastar Pharmaceuticals, Inc.

SG&A Expenses: Corcept vs. Amphastar Over a Decade

__timestampAmphastar Pharmaceuticals, Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 20144037300034916000
Thursday, January 1, 20154697400036949000
Friday, January 1, 20164729800045240000
Sunday, January 1, 20175091800062416000
Monday, January 1, 20185804400081289000
Tuesday, January 1, 201963109000100359000
Wednesday, January 1, 202065157000105326000
Friday, January 1, 202168920000122356000
Saturday, January 1, 202266592000152848000
Sunday, January 1, 202380393000184259000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Biopharma Companies: SG&A Expenses Over Time

In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Corcept Therapeutics Incorporated and Amphastar Pharmaceuticals, Inc. have shown distinct trends in their SG&A expenditures. From 2014 to 2023, Corcept's SG&A expenses surged by over 400%, reflecting its aggressive growth strategy and expansion efforts. In contrast, Amphastar's expenses grew by approximately 100%, indicating a more conservative approach.

By 2023, Corcept's SG&A expenses were nearly double those of Amphastar, highlighting its significant investment in administrative and sales functions. This divergence in financial strategy underscores the different paths these companies have taken in the biopharma landscape. As the industry continues to evolve, monitoring these expenses will be key to understanding each company's future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025